logo

For the Inventor, By the Inventor

Incheon, South Korea

Keum Young Kang

This inventor holds 5 USPTO granted patents and 7 published patent applications. Top assignee: Uppthera. Active years: 2023-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Keum Young Kang. Retrieved from https://idiyas.com/inventor/keum-young-kang

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 5 

% Patents Active = 80.0

Average Co-Inventor Count = 10.0

ph-index = 1


Company Filing History:

goldMedal5 out of 8 
 
Uppthera
 patents

Years Active: 2023-2026

Loading Chart...
5 patents (USPTO):Explore Patents
1. 12741030 - Vanillin derivative compounds inducing selective degradation of PLK1 (2026-09-22),
2. 12403198 - Benzimidazole thiophene derivative compounds inducing selective degradation of PLK1 (2025-09-02),
3. 11939334 - Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers (2024-03-26),
4. 11912710 - Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers (2024-02-27),
5. 11833208 - PLK1 selective degradation inducing compound (2023-12-05),

Title: Keum Young Kang: Innovator in PLK1 Degradation Compounds

Introduction

Keum Young Kang is a prominent inventor based in Incheon, South Korea. He has made significant contributions to the field of biochemistry, particularly in the development of compounds that target polo-like kinase 1 (PLK1) for therapeutic purposes. With a total of 5 patents to his name, Kang is recognized for his innovative approaches to treating PLK1-related diseases.

Latest Patents

Kang's latest patents include groundbreaking work on benzimidazole thiophene derivative compounds that induce selective degradation of PLK1. This invention provides novel compounds that effectively link a PLK1 binding moiety with an E3 ubiquitin ligase-binding moiety through a chemical linker. These compounds are designed to prevent or treat diseases associated with PLK1. Another significant patent involves substituted pyrimido[4,5-b][1,4]diazepines, which also serve as PLK1 degradation inducers. This patent outlines a method for preparing these compounds and their potential applications in treating PLK1-related diseases.

Career Highlights

Kang is currently associated with Uppthera, where he continues to advance his research and development efforts. His work has garnered attention in the scientific community, contributing to the understanding of PLK1's role in various diseases.

Collaborations

Kang collaborates with notable colleagues, including Soo Hee Ryu and Im Suk Min, who share his commitment to innovation in the field of biochemistry.

Conclusion

Keum Young Kang's contributions to the development of PLK1 degradation compounds highlight his role as a leading inventor in the biochemistry sector. His innovative patents pave the way for new therapeutic strategies in treating PLK1-related diseases.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…